Literature DB >> 12173047

Breast cancer cell-derived EMMPRIN stimulates fibroblast MMP2 release through a phospholipase A(2) and 5-lipoxygenase catalyzed pathway.

Paul M Taylor1, Richard J Woodfield, Matthew N Hodgkin, Trevor R Pettitt, Ashley Martin, David J Kerr, Michael J O Wakelam.   

Abstract

Metalloproteinases (MMP) produced by both cancer and normal stromal fibroblast cells play a critical role in the metastatic spread of tumours, however little is known of the regulation of their release. In this report we demonstrate that breast cancer cells in culture release apparently full length soluble EMMPRIN that promotes the release of pro-MMP2 from fibroblasts. The generation of MMP2 is mediated by activation of phospholipase A(2) and 5-lipoxygenase. These results suggest that the production of soluble EMMPRIN, phospholipase A(2) and 5-lipoxygenase activities are sites for potential therapeutic intervention.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12173047     DOI: 10.1038/sj.onc.1205702

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  39 in total

1.  EMMPRIN is secreted by human uterine epithelial cells in microvesicles and stimulates metalloproteinase production by human uterine fibroblast cells.

Authors:  A G Braundmeier; C A Dayger; P Mehrotra; R J Belton; R A Nowak
Journal:  Reprod Sci       Date:  2012-06-22       Impact factor: 3.060

Review 2.  Targeted therapy of chronic myeloid leukemia.

Authors:  Con Sullivan; Cong Peng; Yaoyu Chen; Dongguang Li; Shaoguang Li
Journal:  Biochem Pharmacol       Date:  2010-05-12       Impact factor: 5.858

3.  Resveratrol blocks interleukin-18-EMMPRIN cross-regulation and smooth muscle cell migration.

Authors:  Balachandar Venkatesan; Anthony J Valente; Venkatapuram Seenu Reddy; Deborah A Siwik; Bysani Chandrasekar
Journal:  Am J Physiol Heart Circ Physiol       Date:  2009-06-26       Impact factor: 4.733

4.  EMMPRIN regulates cytoskeleton reorganization and cell adhesion in prostate cancer.

Authors:  Haining Zhu; Jun Zhao; Beibei Zhu; Joanne Collazo; Jozsef Gal; Ping Shi; Li Liu; Anna-Lena Ström; Xiaoning Lu; Richard O McCann; Michal Toborek; Natasha Kyprianou
Journal:  Prostate       Date:  2011-05-11       Impact factor: 4.104

Review 5.  Pancreatic stellate cells--role in pancreas cancer.

Authors:  Max G Bachem; Shaoxia Zhou; Karin Buck; Wilhelm Schneiderhan; Marco Siech
Journal:  Langenbecks Arch Surg       Date:  2008-01-17       Impact factor: 3.445

Review 6.  Cyclophilin-CD147 interactions: a new target for anti-inflammatory therapeutics.

Authors:  V Yurchenko; S Constant; E Eisenmesser; M Bukrinsky
Journal:  Clin Exp Immunol       Date:  2010-03-16       Impact factor: 4.330

7.  Expression of extracellular matrix metalloproteinase inducer (EMMPRIN) and its related extracellular matrix degrading enzymes in the endometrium during estrous cycle and early gestation in cattle.

Authors:  Birendra Mishra; Keiichiro Kizaki; Katsuo Koshi; Koichi Ushizawa; Toru Takahashi; Misa Hosoe; Takashi Sato; Akira Ito; Kazuyoshi Hashizume
Journal:  Reprod Biol Endocrinol       Date:  2010-06-11       Impact factor: 5.211

8.  The glycosylated IgII extracellular domain of EMMPRIN is implicated in the induction of MMP-2.

Authors:  Adriana Papadimitropoulou; Avgi Mamalaki
Journal:  Mol Cell Biochem       Date:  2013-04-06       Impact factor: 3.396

9.  Loss of the Alox5 gene impairs leukemia stem cells and prevents chronic myeloid leukemia.

Authors:  Yaoyu Chen; Yiguo Hu; Haojian Zhang; Cong Peng; Shaoguang Li
Journal:  Nat Genet       Date:  2009-06-07       Impact factor: 38.330

10.  Solution characterization of the extracellular region of CD147 and its interaction with its enzyme ligand cyclophilin A.

Authors:  Jennifer Schlegel; Jasmina S Redzic; Christopher C Porter; Vyacheslav Yurchenko; Michael Bukrinsky; Wladimir Labeikovsky; Geoffrey S Armstrong; Fengli Zhang; Nancy G Isern; James DeGregori; Robert Hodges; Elan Zohar Eisenmesser
Journal:  J Mol Biol       Date:  2009-06-03       Impact factor: 5.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.